GLP-1s in a More Mode: More Indications, More Access | Predictions for 2025

The GLP-1 [glucagon-like peptide 1] agents are poised to become viable options for treating indications beyond type 2 diabetes and obesity. Recent breakthroughs in research for sleep apnea, polycystic ovarian syndrome, Parkinson’s disease and more have demonstrated their potential.

In the coming year, patients will have greater access to these medications than ever before. We’ll see more and more providers integrating GLP-1s into their patients’ treatment plans, indications across various therapeutic areas, and, subsequently, more payers offering coverage for them.